Background: Acute kidney injury (AKI) is one of the most common complications among
INTRODUCTION
The advent of the electronic health record (EHR) with the availability of clinical data in digital form has transformed both clinical care and our ability to analyze that care. 1 Clinical data is the record of clinical care provided to a patient, and chart review of clinical data remains the gold standard for adjudication of clinical research questions. Claims data, based on the use of administrative codes from billable interactions between the patient and a healthcare payer, provides a global view of the patient, since virtually every healthcare interaction generates a bill.
Organizations are developing enterprise data warehouses, sometimes known as integrated data repositories (IDR), which aggregate data from throughout the organization including both clinical data from the EHR and all electronic claims data. 2 Combining the broad picture of a patient seen using claims data, with the accurate clinical information contained within the EHR, could give researchers a more comprehensive view of patient care than is currently available.
Electronic phenotype is a tool to identify and characterize clinical conditions with an automated query of digital clinical record. 3 An electronic phenotype uses a defined set of data elements and logical expressions to accurately identify patients with a set of observable traits from the data contained within a data repository. These queries can be designed to identify patients with a particular condition and, ideally, to clinically stage those conditions to support observational and interventional research. 4, 5 Techniques used include a combination of data mining, natural language processing techniques and regression analyses. 6 Kidney diseases provide a good example of the challenges inherent in analyzing clinical disease data in digital clincal records, and an example of diseases to which electronic phenotyping could be used to good effect. 7, 8 A query of an EHR or IDR using administrative codes alone is very poor at identifying the incidence of acute kidney injury (AKI), or the prevalence of chronic kidney disease (CKD), within any cohort of patients. [9] [10] [11] Furthermore, administrative codes do not reflect any of the disease severity metrics that are important in modern consensus definitions for AKI and CKD. 8, 12 proposes a nomenclature for kidney diseases across the spectrum from AKI to CKD. 15 An episode of AKI which resolves completely within 48 hours is termed "rapid reversal" AKI and is believed to have minimal clinical consequences. An episode of AKI which persists beyond 48
hours is described as "persistent" AKI, while an episode of AKI which results in renal dysfunction that persists beyond 7 days is described using the new term "Acute Kidney
Disease" (AKD). Renal dysfunction persisting 90 days or longer is CKD, and CKD resulting in a need for renal replacement therapy (RRT) is end-stage kidney disease (ESKD). Patients with ESKD can undergo renal transplantation that leaves them with normal renal function or with less-severe CKD that does not require RRT.
No single electronic phenotype has been developed to identify and fully characterize both AKI and CKD within the EHR, although a preliminary and partial CKD phenotype exists 16 and methodologies have been developed to screen for AKI within the EHR or in electronic clinical registries. [17] [18] [19] Here we describe the development and validation of an automated algorithm for comprehensive identification and characterization of kidney health in electronic health records, usable both retrospectively and in real time. To the best of our knowledge this is the first electronic phenotype that combines disparate sources of EHR data to identify stages, duration and renal recovery of both acute and chronic kidney disease.
METHODS

Data and Participants
Using the University of Florida Health (UFH) Integrated Data Repository as Honest
Broker, we have created two single-center longitudinal cohorts that integrated the comprehensive vendor-based inpatient and outpatient EHR (Epic Systems, Verona, Wisconsin, USA) available since 2011 with administrative, laboratory and claims data prior to 2011 and public datasets. 20 The Algorithm Development Cohort used the Declare dataset of 51, 457 patients admitted to UFH between January 2000 and November 2010 ( Figure 1 ).
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Figure 1. Clinical Datasets
The Algorithm Verification Cohort used the PICS cohort that combines EHR and research data for 245 sepsis patients prospectively enrolled in longitudical cohort study at UF between January 2015 and July 2017. 25, 26 The Algorithm Validation Cohort used the AKI EPIC dataset of 84,350 patients admitted to UFH between January 2012 and April 2016. 27 Participants in all cohorts were adults with age  18 years at the time of admission.
With the exception of PICS cohort, dataset represented the population receiving routine clinical care at the study institution. Every admission to the hospital corresponded to unique inpatient encounter. Each dataset included all diagnosis and procedure codes, structured and unstructured clinical data, demographic information, vital signs, laboratory values and medication data for all index inpatient encounters. For each of the patient in the dataset we obtained all prior administrative codes available in UFH IDR using the International Classification of Diseases, 9 th and 10 th revision, clinical modification (ICD-9-CM and ICD-10-CM, respectively) codes. The appropriate mapping was performed for both AKI and CKD to ensure that all appropriate codes were ascertained regardless of whether ICD-9 or ICD-10 codes are used in the EHR (Supplemental Tables 1-5) . For all datasets laboratory data was available for within 12 months prior to index admission and 12 months follow-up. Data elements identified for analysis are included in the supplemental materials (Supplemental Tables 6 and 7) .
Development of the Algorithm
We used Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice
Guideline definitions for AKI and CKD and consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup on renal recovery as conceptual framework for the development of algorithm for comprehensive assessment of kidney health during inpatient hospitalization (eKidneyHealth). 15, 28, 29 Using a comprehensive set of EHR data in the Algorithm Development Cohort, including diagnostic and procedure codes, laboratory results, clinical data and demographic information, we combined a rule-based methodology to develop algorithms and regression analysis previously proven to be replicable with strong predictive values across other institutions. 30 The eKidneyHealth algorithm is a complex algorithm that unifies six rule-based flow diagrams and regression analysis in order to identify and characterize kidney health in any inpatient encounter, either in real-time or in the retrospective datasets ( Figure 2 ).
Figure 2. Master Flow
For every new inpatient encounter, immediatlly upon admission, the algorithm first determines the presence of CKD using all existing historical data prior to index admission ( Figure 3 ).
Figure 3. CKD Identification Flow
The first creatinine value during index admission triggers the assessment of reference creatinine ( Figure 4 ) and staging of CKD ( Figure 5 ) while any subsequent new creatinine value initiates the assessment of AKI stages, renal recovery and dynamic GFR ( Figure 6 ). Common to both the CKD and AKI algorithms is a single "Reference Creatinine" algorithm used to identify and calculate, using available data, every patient's reference creatinine. It represents a patient's creatinine in the steady state, before any new AKI occurs, and/or after the patient recovers from any pre-existing AKI. The flows are built from data inputs, conditional decision points, search and/or calculations needed, and outputs. To identify and stage CKD for each inpatient encounter the CKD Identification, Reference Creatinine and CKD Staging algorithms are run once only using data from the day of admission and historical data.
To identify and stage any new AKI during the inpatient encounter the Reference Creatinine, AKI Identification and AKI Staging algorithms are run once using data from the day of admission and historical data, and then these three algorithms are run again every time a new creatinine measurement is detected.This makes sure that any AKI that develops during an inpatient encounter is captured, and insures that the correct reference creatinine is used in doing so.
The algorithm was written in both Python 2.7 13 and SciPy 1.0.0 31 software. Data elements were extracted from the dataset, transformed and cleaned as needed, and then organized into Python data structures for fast query of a patients' history. Queries were developed and unit-tested for each object, and then combined into Python routines to implement the logic of the algorithms. Each patient record in the algorithm verification PICS dataset of 245 sepsis patients contains clinical adjudication for CKD, AKI and renal recovery status performed by two independent nehrologists as a part of a study protocol. 26 Further development and editing of the code were done using this database using clinical adjusication as the gold standard. Code subroutines were revised in an iterative manner by running the subroutines on the development and then verification cohorts, with the results compared to previous clinical adjudication.
Identification and staging of CKD
The CKD Identification Flow is used to determine if the patient has any evidence of CKD or ESKD, and to distinguish between patients with pre-existing CKD and those with new onset AKI ( Figure 4 ). The algorithm first uses all available administrative codes in patient's medical record to identify patients with CKD, ESKD and any history of kidney transplantation using previously validated combination of ICD-9 or ICD-10 codes (Supplemental Tables 1-5 The reference creatinine level from the Reference Creatinine Flow is used as the standardized serum creatinine in that formula.
Determination of Reference Creatinine
The Reference Creatinine Flow is used to calculate a reference serum creatinine level The ability of clinician experts, with access to all patient data within a medical chart, to identify patients with disease is widely accepted as the gold standard. We enlisted three physicans (a nephrologist, an internist and a surgeon) and a medical student trained in the clinical consensus definitions of AKI and CKD to independently review the validation cohort of patients, using their EHR, to determine if the patients had CKD at the time of admission and/or AKI that developed during the hospitalization. Reviewers used physician notes, nursing notes and laboratory results to search for clinical evidence of CKD and/or AKI. Any differences in ascertainment of either CKD or AKI were arbitrated in discussion between the three reviewers while reviewing the EHR for the patient. We used the AKI Code Algorithm on the same validation cohort of patients to identify those patients who developed AKI during the hospitalization using administrative codes only. We then compared the ability of the full phenotype to identify CKD and/or AKI compared to the clinicians, and compared the ability of the full phenotype to identify AKI compared to the AKI Code Algortihm. Sensitivity, specificity, positive and negative predictive values and overall accuracy (the proportion of true classification including true positives plus true negatives) for ascertainment by the phenotype compared to ascertainment by the reference techniques were calculated with exact binomial confidence intervals. We also then reviewed the EHRs of the patients where there was a mismatch between identification by phenotype compared to identification by clinician, as an indication of how the phenotype failed and might be improved in the future.
The review sample for the phenotype algorithm validation was created by randomly selecting inpatient encounters from the AKI Epic database based on CKD status while stratifying each group for reference creatinine, AKI status and renal recovery. To determine how many charts would be needed for review in each subgroup we assumed that, due to the selection criteria, the expected incidence of AKI and CKD in the validation cohort would be 50% and thus a p0 for power calculation would be 0.5. We specified an odds ratio of 2.0, an α of 0.05 with a 2-sided test and a β of 0.8. The power calculation, given these criteria, indicated a necessary sample size of 137 for both cases and controls or a total of 274 charts. Thus in each subgroup the patient encounters with the 25 highest reference creatinines and the 25 lowest reference creatinines were chosen for review, for a total of 300 charts. The medical record numbers for those patient encounters were pulled and used to review each patient's record in the Epic EHR.
Statistical analyses were performed with SAS (version 9.4; SAS Institute, Inc, Cary, NC) and R software.
Data collection and analysis
The 
RESULTS
Clinical Characteristics
The basic clinical charactristics for patients without ESKD was assessed for all 3 cohorts (Table 1 ). In the full cohort of 49,522 patients, approximately 51% of the population were male, and the mean age was 56 years old. The percentage of AKI and CKD was both higher among the verification cohort. 
Distribution of chronic kidney disease groups
Among 149,136 encounters of validation cohort, 12.4% had CKD by Medical history.
Using creatinine criteria, percent of patients with CKD identified increased to 16.9% (Table 2) . 
AKI Charachtristics
Among 130,081 encounters who had sufficient data for AKI phenotyping after excluding those with end-stage renal disease on admission, AKI during hospitalization was identified in 21% of encounters (Table 3 ). The maximum AKI stage was mostly stage 1 (63%), while AKI stage 2 and 3 were the maximum stage identified in 19% and 18% of the patients, respectively.
Twelve percent of patients developed more than one episode of AKI. Reasons for mismatches between phenotyping algorithm and manual chart review includes: a Reference creatinine wrong based on erroneous laboratory measurement (n=2) b Wrong reference creatinine due to insufficient creatinine history for CKD patient (n=2) and Wrong reference creatinine due to wrong CKD code assignment (n=3)
DISCUSSION
Acute kidney injury and chronic kidney disease are common, interrelated, and cause significant morbidity and mortality for patients. 32, 33 Outcomes are the worst for patients with severe AKI and/or CKD, but they degrade even for patients with mild and moderate disease. 34, 35 The ability to automatically identify and stage patients with AKI and CKD within a data repository of clinical data would facilitate clinical and health services research and, if done in real time, could greatly facilitate clinical decision support. 22, 36 In this work we developed and validated a novel methodology to identify adult patients with kidney disease using both clinical and claims data in an integrated data repository. We applied the technique of electronic phenotyping in a large retrospective cohort of hospitalized patients to translate a clinician's approach to assessing AKI and CKD into a set of computer algorithms. We developed a phenotype for adult kidney health that allowed us to identify patients with both AKI and CKI, to clinically stage those diseases and to assess any recovery from AKI that occurs during the inpatient hospital stay.
The overall algorithm is constructed from three algorithms to identify CKD plus three algorithms to identify AKI, with both using a common "Reference Creatinine" algorithm used to identify every patient's baseline creatinine and which is updated every time a new serum creatinine value is identified. The outputs from the overall algorithm include CKD by medical history and/or creatinine criteria including ESKD, AKD and recovered AKI, KDIGO G-stage of any CKD, new and persistent AKI, recovery from AKI and from AKD, and KDIGO stage of any AKI.
Kidney disease is commonly divided clinically into acute kidney injury (AKI) and chronic kidney disease (CKD), although both diseases exist on a spectrum of overall kidney health. 37 While AKI is often seen as an acute complication of surgery, as drug toxicity or as a result of trauma or sepsis, CKD is a chronic illness most commonly associated with diabetes and/or hypertension. Despite this clinical and logical separation, there is significant overlap between the entities. 38 An episode of AKI can become CKD if there is no recovery after the initial insult.
Patients with CKD are at higher risk for developing AKI compared to patients without CKD, while an episode of AKI puts a patient at higher risk for developing CKD even if the episode of AKI resolves completely. Both AKI and CKD increase a patient's risk for other diseases, especially cardiovascular diseases.
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Patients with clinical disease can be identified within a database of clinical information, as is contained within a database of EHRs, or they can be identified within a database billing or claims data made up of administrative codes as in the National Inpatient Sample. 40, 41 Research using clinical data once required laborious and time-consuming manual review of paper charts, but can now be done quickly through automated review of EHRs. Clinical data contains the full richness of a patient's medical history, but is limited to information from only one provider, one hospital, or at most one delivery system, and care provided outside of those constraints is not available for analysis. 42 Claims data can provide a global picture of care provided to any patient, but it cannot provide a complete clinical picture as there is often minimal or no information on disease severity and coding accuracy can be problematic. 43, 44 While the clinical information contained within billing data is becoming more dense and granular with every revision of the coding systems, using billing data in the analysis of clinical disease requires much more clinical information than is currently available in claims data. An automated approach to identifying and characterizing disease that combines the global picture seen in administrative codes, with the clinical detail provided in EHR data, could provide accurate and reliable inferences about the presence and severity of clinical illness. 45, 46 Originally developed by genomics researchers, to query EHRs to accurately capture all patients with rare genetic diseases, the electronic phenotype is finding wider use in both clinical and health services research applications. 47 The goal in electronic phenotyping is to accurately identify patients with a specific observable trait from the large volumes of imperfect and/or incomplete practice-based data contained within the EHR 3 The Electronic Medical Records and Genomics (eMERGE) Network, an international consortium of genetics researchers, publishes best practices in developing and using phenotyping algorithms and helped establish an online repository, the Phenotype Knowledgebase (https://phekb.org), where phenotypes can be published and then validated at other participating institutions. 30, 48 Phenotypes that include clinical data such as medication records, clinical progress notes, and laboratory and radiology data notes along with administrative codes have demonstrated much improved disease identification as measured by positive and negative predictive values compared to identification using administrative data alone. 42, 49 We evaluated the ability of the kidney health phenotype to identify patients with kidney disease against the gold standard of clinical chart review and against the process of identifying patients solely by using administrative data. The performance of the phenotype in identifying AKI and CKD exceeds existing tools and greatly improves upon the ability to capture AKI using administrative codes alone. [50] [51] [52] Importantly the phenotype performs well across the spectrum of disease severity including minor stages of AKI. Recent studies have demonstrated the ability of identification tools that emphasize severe kidney injury, such as the Major Adverse Kidney
Events by 30 days (MAKE30) composite of death, new renal replacement therapy, or persistent renal dysfunction to retrospectively identify AKI in the EHR with high sensitivity and specificity. 53 However methods to capture mild and moderate AKI in the EHR are lacking. 7 Mild to moderate AKI is much more common than severe AKI, and has become much more appreciated with the introduction of consensus definitions for AKI. 54 Recent work using modern consensus definitions of AKI have shown that when properly defined AKI is one of the most prevalent complications seen in hospitalized patients, is associated with other adverse events, results in an increase in resource utilization and increases in both short-and long-term mortality. 32, 34, 55, 56 The ability to more accurately identify AKI and CKD in retrospective analysis of large medical databases will improve the ability to measure the costs of care, the costs of complications of care and the assessment of provider clinical performance. 57, 58 Perhaps even more importantly, the ability to accurately identify AKI in real-time or close to real-time analysis of data within the EHR may lead to earlier and better care for the patients that have just been identified with new or worsening AKI.
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Limitations
This work, despite the performance of the phenotype, has some significant limitations.
One important limitation is related to how the the electronic phenotype was developed. To the extent that the phenotype relies on administrative codes for AKI and CKD it is dependant upon accurate and precise coding of diseases in the EHR, a reality that is rarely if ever achieved.
Since identification of both AKI and CKD are dependant upon by changes in serum creatinine and in a determination of baseline creatinine, the phenotype misses other important clinical signs of kidney injury and illness. Oliguria, or decreased urine output, is an important predictor and early sign of kidney injury and is not captured in this phenotype. Changes is urine and serum biomarkers, an important and evolving technology to identify AKI and CKD, is not captured in the phenotype. Finally the phenotype as built is largely diagnosis agnostic. While it does capture administrative codes for a wide variety of kidney diseases, at the end it just identifies a patient with AKI and/or CKD with KDIGO staging, but it does not capture specific etiologies of either condition and thus misses important clinical information related to etiology.
The performance of the phenotype needs to be further evaluated, to determine its ability to accurately measure the temporal aspects of AKI and CKD and renal recovery if any, and to determine its performance in the outpatient setting.
Conclusion
We have described the development and validation of an electronic phenotype for kidney health in hospitalized adult patients. This tool could improve studies into the epidemiology of AKI and CKD, could improve the assessment of the costs of these conditions and the quality of care, and could hasten the development of effective and early alerts for AKI. Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404.01
SUPPLEMENTAL TABLES
Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404.02
Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage kidney disease 404.03
Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage kidney disease 404. 10 Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404.11
Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404. 12 Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage kidney disease 404. 13 Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage kidney disease 404. 90 Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404. 91 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404.92
Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage kidney disease 404. 93 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage kidney disease 581
Nephrotic syndrome 581.0
Nephrotic syndrome with lesion of proliferative glomerulonephritis 581. 1 Nephrotic syndrome with lesion of membranous glomerulonephritis 581. 2 Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis 581. 3 Nephrotic syndrome with lesion of minimal change glomerulonephritis 581. 8 Nephrotic syndrome with other specified pathological lesion in kidney 581. 81 Nephrotic syndrome in diseases classified elsewhere 581.89
Nephrotic syndrome with other specified pathological lesion in kidney 581. 9 Nephrotic syndrome with unspecified pathological lesion in kidney 582
Chronic glomerulonephritis 582.0
Chronic glomerulonephritis with lesion of proliferative glomerulonephritis 582. 1 Chronic glomerulonephritis with lesion of membranous glomerulonephritis 582. 2 Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis 582.4
Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis 582. 8 Chronic glomerulonephritis with other specified pathological lesion in kidney 582. 81 Chronic glomerulonephritis in diseases classified elsewhere 582.89
Chronic glomerulonephritis with other specified pathological lesion in kidney 582. 9 Chronic glomerulonephritis with unspecified pathological lesion in kidney 583
Nephritis and nephropathy, not specified as acute or chronic 583.0
Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis 583. 1 Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis 583. 2 Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis 583. 4 Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis 583. 6 Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis 583. 7 Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis 583. 8 Nephritis and nephropathy not specified as acute or chronic with other specified pathological lesion in kidney 583.81
Nephritis and nephropathy, not specified as acute or chronic, in diseases classified elsewhere 583.89
Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney 583. 9 Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney 585
Chronic kidney disease (ckd) 585. Other specified disorders resulting from impaired renal function 588. 81 Secondary hyperparathyroidism (of renal origin) 588.89
Other specified disorders resulting from impaired renal function 588. 9 Unspecified disorder resulting from impaired renal function 753. 13 Polycystic kidney, autosomal dominant ICD-10-CM Diagnosis I12.0 Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage kidney disease I12. 9 Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease I13.0
Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease I13. 1 Hypertensive heart and chronic kidney disease without heart failure I13. 10 Hypertensive heart and chronic kidney disease without heart failure with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease I13.11
Hypertensive heart and chronic kidney disease without heart failure with stage 5 chronic kidney disease, or end stage kidney disease I13. 2 Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage kidney disease N01
Rapidly progressive nephritic syndrome N01.0
Rapidly progressive nephritic syndrome with minor glomerular abnormality N01. 1 Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions N01. 2 Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis N01. 3 Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis N01. 4 Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis N01.5
Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis N01. 6 Rapidly progressive nephritic syndrome with dense deposit disease N01. 7 Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis N01. 8 Rapidly progressive nephritic syndrome with other morphologic changes N01. 9 Rapidly progressive nephritic syndrome with unspecified morphologic changes N02.0
Recurrent and persistent hematuria with minor glomerular abnormality N02.1
Recurrent and persistent hematuria with focal and segmental glomerular lesions N02. 2 Recurrent and persistent hematuria with diffuse membranous glomerulonephritis N02. 3 Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis N02. 4 Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis N02. 5 Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis N02. 6 Recurrent and persistent hematuria with dense deposit disease N02.7
Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis N02. 8 Recurrent and persistent hematuria with other morphologic changes N02.9
Recurrent and persistent hematuria with unspecified morphologic changes N03
Chronic nephritic syndrome N03.0
Chronic nephritic syndrome with minor glomerular abnormality N03.1
Chronic nephritic syndrome with focal and segmental glomerular lesions N03. 2 Chronic nephritic syndrome with diffuse membranous glomerulonephritis N03. 3 Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis N03. 4 Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis N03. 5 Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis N03. 6 Chronic nephritic syndrome with dense deposit disease N03. 7 Chronic nephritic syndrome with diffuse crescentic glomerulonephritis N03. 8 Chronic nephritic syndrome with other morphologic changes N03. 9 Chronic nephritic syndrome with unspecified morphologic changes N04 Nephrotic syndrome N04.0
Nephrotic syndrome with minor glomerular abnormality N04. 1 Nephrotic syndrome with focal and segmental glomerular lesions N04. 2 Nephrotic syndrome with diffuse membranous glomerulonephritis N04. 3 Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis N04. 4 Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis N04. 5 Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis N04. 6 Nephrotic syndrome with dense deposit disease N04. 7 Nephrotic syndrome with diffuse crescentic glomerulonephritis N04. 8 Nephrotic syndrome with other morphologic changes N04. 9 Nephrotic syndrome with unspecified morphologic changes N05 Unspecified nephritic syndrome N05.0
Unspecified nephritic syndrome with minor glomerular abnormality N05. 1 Unspecified nephritic syndrome with focal and segmental glomerular lesions N05. 2 Unspecified nephritic syndrome with diffuse membranous glomerulonephritis N05. 3 Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis N05. 4 Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis N05. 5 Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis N05. 6 Unspecified nephritic syndrome with dense deposit disease N05. 7 Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis N05. 8 Unspecified nephritic syndrome with other morphologic changes N05. 9 Unspecified nephritic syndrome with unspecified morphologic changes N06
Isolated proteinuria with specified morphological lesion N06.0
Isolated proteinuria with minor glomerular abnormality N06. 1 Isolated proteinuria with focal and segmental glomerular lesions N06. 2 Isolated proteinuria with diffuse membranous glomerulonephritis N06. 3 Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis N06.4
Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis N06. 5 Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis N06. 6 Isolated proteinuria with dense deposit disease N06. 7 Isolated proteinuria with diffuse crescentic glomerulonephritis N06. 8 Isolated proteinuria with other morphologic lesion N06. 9 Isolated proteinuria with unspecified morphologic lesion N07
Hereditary nephropathy, not elsewhere classified N07.0
Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality N07. 1 Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions N07. 2 Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis N07. 3 Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis N07. 4 Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis N07. 5 Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis N07. 6 Hereditary nephropathy, not elsewhere classified with dense deposit disease N07. 7 Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis N07. 8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions N07. 9 Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions E08. 2 Diabetes mellitus due to underlying condition with kidney complications E08. 21 Diabetes mellitus due to underlying condition with diabetic nephropathy E08. 22 Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.29
Diabetes mellitus due to underlying condition with other diabetic kidney complication E09. Other specified diabetes mellitus with kidney complications E13. 21 Other specified diabetes mellitus with diabetic nephropathy E13. 22 Other specified diabetes mellitus with diabetic chronic kidney disease E13.29
Other specified diabetes mellitus with other diabetic kidney complication N25 Disorders resulting from impaired renal tubular function N25. 8 Other disorders resulting from impaired renal tubular function N25. 81 Secondary hyperparathyroidism of renal origin N25.89
Other disorders resulting from impaired renal tubular function N25. 9 Disorder resulting from impaired renal tubular function, unspecified Q61 Cystic kidney disease Q61. 2 Polycystic kidney, adult type Q61. 3 Polycystic kidney, unspecified Q61. 4 Renal dysplasia Q61. 5 Medullary cystic kidney Q61. 8 Other cystic kidney diseases Q61. 9 Cystic kidney disease, unspecified N18. 1 Chronic kidney disease, stage 1 N18. 2 Chronic kidney disease, stage 2 (mild) N18. 3 Chronic kidney disease, stage 3 (moderate) N18. 4 Chronic kidney disease, stage 4 (severe) 
